Monthly Prescribing Reference

First Generic Version of Sandostatin LAR Depot Now Available

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...
Nasdaq

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
ascopubs.org

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine ...

Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of ...
Drug Store News

Teva intros generic Sandostatin LAR Depot

Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe ...
Medscape

Pasireotide More Effective Than Octreotide for Acromegaly

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...
Healio

Generic version of injectable acromegaly treatment launches in US

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced the launch of a generic form of Sandostatin LAR Depot. The medication is ...
Nature

Antitumor effects of octreotide LAR, a somatostatin analog

Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The PROMID study group now reports that octreotide ...
Monthly Prescribing Reference

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
FiercePharma

Thanks to complex manufacturing, Novartis expects blockbuster Sandostatin LAR to steer clear of generics in 2020

First approved in 1998, Novartis’ Sandostatin LAR is an old-but-reliable drug when it comes to sales. And that's not likely to change this year—or so the Swiss drugmaker figures. In its 2020 guidance, ...
Healio

Octreotide Acetate

Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (such as carcinoid tumors, vasoactive intestinal peptide tumors) that are ...